HFM
AYTU icon

Hartford Financial Management’s AYTU BioPharma AYTU Stock Holding History

Hartford Financial Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2
Closed -$15K – 351
2017
Q4 		$15K Buy
+2
New +$23.9K 0.01% 235

Other funds holding AYTU

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hartford Financial Management's AYTU Position: Q1 2018 in Review

Hartford Financial Management sold out of AYTU BioPharma (AYTU) in Q1 2018, closing a stake of 2 shares — an estimated $15K sold.

Hartford Financial Management first reported a position in AYTU in Q4 2017 and held it in 1 quarter. The position peaked at $15K in Q4 2017. 10 funds tracked by Wall St. Rank hold AYTU as of Q1 2018.

  • Hartford Financial Management reported no remaining AYTU BioPharma position as of Q1 2018 after selling out during the quarter.
  • Hartford Financial Management sold 2 AYTU BioPharma shares in Q1 2018, an estimated $15K.
  • Hartford Financial Management first reported a position in AYTU BioPharma in Q4 2017 and held it in 1 quarter.
  • Hartford Financial Management's AYTU BioPharma position peaked at $15K in Q4 2017.
  • 10 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2018.

Based on Hartford Financial Management's 13F filing for Q1 2018, filed 10 Apr 2018.